Dystrophin Market
Dystrophin Market - Global Industry Assessment & Forecast
Segments Covered
- By Product Exondys51, Translarna, Emflaza, Others
- By Approach Exon Skipping, Anti-Inflammatory Therapy, Stop Codon Read-Through, Others Approaches
- By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 1.46 Billion |
Revenue 2030: | USD 29.53 Billion |
Revenue CAGR (2023 - 2030): | 45.60% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Research Methodology: Dystrophin Market by Product by Approach by Region - Global Market Assessment, 2021 - 2028
Secondary Research
Primary Research:
Data Triangulation and Market Size Estimations
FAQ
Frequently Asked Question
What is the global demand for Dystrophin in terms of revenue?
-
The global Dystrophin valued at USD 1.46 Billion in 2022 and is expected to reach USD 29.53 Billion in 2030 growing at a CAGR of 45.60%.
Which are the prominent players in the market?
-
The prominent players in the market are PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis, Pharmaceuticals among others..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 45.60% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Dystrophin include
- Emergence of Mutation-Specific Therapies, Rising Incidence of the Condition, and Improved Diagnostics
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Dystrophin in 2022.